Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 3 Myelodysplastic Syndromes 3 Multiple Myeloma 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 Leukemia 3 Recurrence 2 Pancreatic Neoplasms 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Sarcoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Oligodendroglioma 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Myeloproliferative Disorders 1 Lymphoma 1 Leukemia, Myeloid 1 Leukemia, Biphenotypic, Acute 1 Hodgkin Disease 1 Colorectal Neoplasms 1 Astrocytoma 1

Interventions

Doxorubicin 27 Cyclophosphamide 26 Radiotherapy 16 Gemcitabine 16 Filgrastim 11 pembrolizumab 10 pazopanib 10 Radiation 9 Docetaxel 9 Cisplatin 9 fludarabine 7 Trabectedin 7 Ipilimumab 7 Ifosfamide 7 Granulocyte Colony-Stimulating Factor 7 Etoposide 7 Carboplatin 7 Busulfan 7 Bevacizumab 7 olaratumab 6 Temozolomide 6 Peripheral Blood Stem Cell Transplantation 6 Nivolumab 6 Mesna 6 Melphalan 6 selinexor 5 Leucovorin 5 Irinotecan 5 Celecoxib 5 Bortezomib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Sarcoma × plerixafor × Clear all

NCT03240861 2023-11-01

NYESO SCT

Jonsson Comprehensive Cancer Center

Phase 1 Terminated

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡